ICU Medical (NASDAQ:ICUI) Cut to "Hold" at StockNews.com

ICU Medical (NASDAQ:ICUI - Get Free Report) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a report issued on Saturday.

ICUI has been the topic of a number of other reports. Raymond James dropped their target price on shares of ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a report on Friday. KeyCorp dropped their price target on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Finally, Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $192.67.

ICU Medical Price Performance

ICUI stock traded down $0.75 during trading on Friday, hitting $143.59. The company had a trading volume of 224,255 shares, compared to its average volume of 274,904. The business has a 50 day moving average of $140.68 and a 200 day moving average of $154.77. The firm has a market capitalization of $3.53 billion, a price-to-earnings ratio of -31.42 and a beta of 0.87. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical has a fifty-two week low of $100.91 and a fifty-two week high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The company had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. During the same period in the prior year, the business posted $0.96 EPS. The business's revenue for the quarter was up 6.7% compared to the same quarter last year. As a group, research analysts predict that ICU Medical will post 4.11 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in ICU Medical by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier's stock valued at $416,176,000 after acquiring an additional 17,805 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of ICU Medical by 7.4% during the fourth quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier's stock worth $109,920,000 after purchasing an additional 49,108 shares during the period. Dimensional Fund Advisors LP grew its position in ICU Medical by 18.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock valued at $83,788,000 after purchasing an additional 82,982 shares in the last quarter. Northern Trust Corp grew its position in ICU Medical by 11.1% during the fourth quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier's stock valued at $62,431,000 after purchasing an additional 40,187 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in ICU Medical by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 304,155 shares of the medical instruments supplier's stock valued at $47,196,000 after buying an additional 3,048 shares during the period. Hedge funds and other institutional investors own 96.10% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.